Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25569482 | 0.95 | KMT2A (0.31) | KMT2ATDP1HDAC1HDAC8HDAC6 | |
| SCHEMBL25569470 | 0.86 | KDM4E (0.32) | KMT2ATDP1HDAC1HDAC8HDAC6 | |
| SCHEMBL25569495 | 0.85 | KMT2A (0.30) | KMT2ATDP1 | |
| SCHEMBL25569471 | 0.82 | ALDH1A1 (0.31) | — | |
| SCHEMBL24197476 | 0.81 | HTR1B (0.45) | KMT2ATDP1HDAC1HDAC8HDAC6 | |
| SCHEMBL25569496 | 0.80 | — | — | |
| SCHEMBL25569478 | 0.78 | HDAC1 (0.32) | KMT2AHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL25569474 | 0.78 | KDM4E (0.32) | KMT2AHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL24197468 | 0.78 | MAPT (0.34) | KMT2AHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL25569477 | 0.78 | HDAC1 (0.32) | KMT2AHDAC1HDAC8HDAC6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | KMT2A 910/4885TDP1 982/4885HDAC1 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.